Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

F-903

Supelco

Fluphenazine dihydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C22H26N3OSF3 · H2Cl2
Numero CAS:
146-56-5
Peso molecolare:
510.44
Numero MDL:
MFCD00055212
Codice UNSPSC:
41116107
ID PubChem:
329799780
NACRES:
NA.24

Grado

certified reference material

Stato

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

1.0 mg/mL in methanol (as free base)

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCC[N+H]4CC[N+H](CC4)CCO.[Cl-].[Cl-]

InChI

1S/C22H26F3N3OS.2ClH/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;;/h1-2,4-7,16,29H,3,8-15H2;2*1H
MBHNWCYEGXQEIT-UHFFFAOYSA-N

Informazioni sul gene

human ... DRD2(1813)

Descrizione generale

Fluphenazine, sold under the trade name Prolixin®, is a typical antipsychotic prescribed for treatment of schizophrenia, mania, bipolar disorder and dementia. This certified solution standard is suitable for fluphenazine testing methods by GC/MS or LC/MS for clinical toxicology, forensic analysis, or urine drug testing applications.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Prolixin is a registered trademark of E.R. Squibb & Sons, LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Alcindo Busanello et al.
Pharmacology, biochemistry, and behavior, 101(2), 307-310 (2012-01-24)
Treatment with classical neuroleptics in humans can produce a serious side effect, known as tardive dyskinesia (TD). Here, we examined the possible neuroprotective effects of resveratrol, a polyphenol compound contained in red grapes and red wine, in an animal model
Yu-Wen Chen et al.
European journal of pharmacology, 693(1-3), 31-36 (2012-08-29)
The aim of this study was to examine whether thioxanthine-type antipsychotics (chlorprothixene and cis(z)-flupenthixol) and phenothiazine-type antipsychotics (chlorpromazine and fluphenazine) produced spinal anesthesia. Using a rat model of intrathecal injection, we evaluated spinal anesthesia of antipsychotic drugs (chlorprothixene, cis(z)-flupenthixol, chlorpromazine
David G Goodwin et al.
The Journal of parasitology, 97(1), 148-151 (2011-02-26)
An increasing interest in the association of the presence of antibodies to Toxoplasma gondii and the development of schizophrenia in patients has been generated over the last several years. Some antischizophrenia agents have been shown to have activity against T.
Irena Popović et al.
Psychiatria Danubina, 23(4), 384-388 (2011-11-15)
Schizophrenia is a severe chronic psychiatric disorder for which treatment compliance is important in the prevention of relapse. Second generation antipsychotics (SGA), such as Risperidone, have been found to be more effective in the treatment of such patients than the
Antipsychotic medication for early-episode schizophrenia.
John R Bola et al.
Schizophrenia bulletin, 38(1), 23-25 (2011-11-26)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.